ATM Knockout cell line (22Rv1)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ATM (ATM serine/threonine kinase) encodes a PI3K-related serine/threonine kinase that acts as a master regulator of the cellular response to DNA double-strand breaks. ATM phosphorylates multiple checkpoint and repair proteins, including p53, BRCA1, CHK2, and NBS1, to coordinate cell cycle arrest, DNA repair, and genome stability. It is a key component of DNA damage checkpoint signaling pathways and is widely studied in genome maintenance and stress response mechanisms.

22Rv1 is a human prostate carcinoma epithelial cell line derived from the CWR22R xenograft, which was serially propagated in nude mice after castration-induced regression and relapse of the parental androgen-dependent CWR22 tumor. The cells express prostate-specific antigen (PSA) and retain androgen receptor expression, with growth weakly stimulated by dihydrotestosterone. 22Rv1 cells are tumorigenic in nude mice and are widely used as a model for studying castration-resistant prostate cancer, androgen receptor signaling, tumor progression, and therapeutic responses.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.